Cerliponase alfa
Contents
Description
Cerliponase alfa is a recombinant human tripeptidyl peptidase 1 (TPP1) enzyme replacement therapy administered via intracerebroventricular infusion. It is specifically approved for neuronal ceroid lipofuscinosis type 2 (CLN2) and represents the first enzyme replacement therapy to cross the blood-brain barrier for lysosomal storage disorders. While approved for CLN2, it has been studied in other NCL subtypes including CLN11.
Indications & Therapeutic Use
neuronal ceroid lipofuscinosis type 2, Batten disease
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Cerliponase alfa — GNH India
6 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Cerliponase alfa products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | cerliponase alfa |
| Brands | 1 brand available |
| Active Ingredient | cerliponase alfa |
| Drug Class | neuronal ceroid lipofuscinosis type 2 |
| Manufacturer | BioMarin Pharmaceutical |
| Dosage Forms | intracerebroventricular infusion, 150mg/5mL |
| Medical Code | A16AB17 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 30 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT01907087 |
| Countries | 8 countries |